The Heads of Medicines Agencies, an umbrella group for regulators in 30 European Union countries, plans to launch a “joint action” with the European Commission and the European Medicines Agency to bolster required clinical trial reporting by drug makers and universities.
The move, which emerged from an HMA meeting last week, follows ongoing criticism that too many clinical trial sponsors fail to report study results, an issue that has embroiled drug makers, universities, and policy makers in the U.S. and Europe. The topic has been a flash point following several scandals over safety or efficacy data that were not publicly shared, prompting a greater push for transparency.
About the Author Reprints
